These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 23484692)
1. [Early detection of MRD in peripheral blood after induction chemotherapy of newly diagnosed patients with AML and its correlation with curative effects]. Zhong XS; Lan F; Cui X; Jiang NG; Zhu HL; Jia YQ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):57-61. PubMed ID: 23484692 [TBL] [Abstract][Full Text] [Related]
2. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia]. Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363 [TBL] [Abstract][Full Text] [Related]
3. [Prognostic significance of minimal residual disease detected by multiparameter flow cytometry in acute myeloid leukemia]. Wang YZ; Liu YR; Zhu HH; Wu HH; Cao H; Chan Y; Hao L; Jiang B; Huang XJ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):551-6. PubMed ID: 19549362 [TBL] [Abstract][Full Text] [Related]
4. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155 [TBL] [Abstract][Full Text] [Related]
5. [Dynamically monitoring minimal residual disease in acute leukemia after complete remission by multiparameter flow cytometry and its relation with prognosis]. Sun NN; Gan SL; Sun H; Zhang QT; Liu YF; Xie XS Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):339-42. PubMed ID: 23628028 [TBL] [Abstract][Full Text] [Related]
6. [Predictable recurrence by regular monitoring minimal residual disease with flow cytometry in the patients with both AML and ALL: a single-center study of 163 cases]. Tong CR; Wang H; Yang JF; Lin YH; Zhang X; Zhao J; Fei XH; Gu JY; Lu DP Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):748-51. PubMed ID: 22339910 [TBL] [Abstract][Full Text] [Related]
7. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400 [TBL] [Abstract][Full Text] [Related]
8. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol]. Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166 [TBL] [Abstract][Full Text] [Related]
9. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance]. Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951 [TBL] [Abstract][Full Text] [Related]
10. [Clinical significance of dynamic monitoring the minimal residual disease in childhood B-lineage acute lymphoblastic leukemia by multiparameter flow cytometry]. Guo DD; Zhao WL; Zhang YL; Pang L; Che L; He HL; Chai YH; Ji ZH; Ji XQ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1346-51. PubMed ID: 23257430 [TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol. Buldini B; Rizzati F; Masetti R; Fagioli F; Menna G; Micalizzi C; Putti MC; Rizzari C; Santoro N; Zecca M; Disarò S; Rondelli R; Merli P; Pigazzi M; Pession A; Locatelli F; Basso G Br J Haematol; 2017 Apr; 177(1):116-126. PubMed ID: 28240765 [TBL] [Abstract][Full Text] [Related]
12. [Effect of Flow Cytometric MRD Detection at Different Time Points during AML Chemotherapy on Prognosis]. Ju RX; Sun FQ; Wang YH Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug; 32(4):1051-1057. PubMed ID: 39192397 [TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. Freeman SD; Virgo P; Couzens S; Grimwade D; Russell N; Hills RK; Burnett AK J Clin Oncol; 2013 Nov; 31(32):4123-31. PubMed ID: 24062403 [TBL] [Abstract][Full Text] [Related]
14. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. ; Langebrake C; Creutzig U; Dworzak M; Hrusak O; Mejstrikova E; Griesinger F; Zimmermann M; Reinhardt D J Clin Oncol; 2006 Aug; 24(22):3686-92. PubMed ID: 16877738 [TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. Inaba H; Coustan-Smith E; Cao X; Pounds SB; Shurtleff SA; Wang KY; Raimondi SC; Onciu M; Jacobsen J; Ribeiro RC; Dahl GV; Bowman WP; Taub JW; Degar B; Leung W; Downing JR; Pui CH; Rubnitz JE; Campana D J Clin Oncol; 2012 Oct; 30(29):3625-32. PubMed ID: 22965955 [TBL] [Abstract][Full Text] [Related]
16. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse. Al-Mawali A; Gillis D; Lewis I Cytometry B Clin Cytom; 2009 Mar; 76(2):91-101. PubMed ID: 18727068 [TBL] [Abstract][Full Text] [Related]
17. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Buccisano F; Maurillo L; Gattei V; Del Poeta G; Del Principe MI; Cox MC; Panetta P; Consalvo MI; Mazzone C; Neri B; Ottaviani L; Fraboni D; Tamburini A; Lo-Coco F; Amadori S; Venditti A Leukemia; 2006 Oct; 20(10):1783-9. PubMed ID: 16838027 [TBL] [Abstract][Full Text] [Related]
18. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia. Zelezníková T; Babusíková O Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719 [TBL] [Abstract][Full Text] [Related]
19. [Minimal residual disease detection in acute leukemia patients by flow cytometric assay of cross-lineage antigen expression]. Cho YU; Park CJ; Cha CH; Chi HS; Jang S; Kim MJ; Lee KH; Lee JH; Lee JH; Seo JJ; Im HJ Korean J Lab Med; 2010 Dec; 30(6):533-9. PubMed ID: 21157135 [TBL] [Abstract][Full Text] [Related]
20. [Flow cytometric monitoring of minimal residual diseases in patients with acute leukemia after allogeneic hemapoietic stem cell transplantation]. Gao YQ; Wu T; Wang H; Tong CR; Zhang WJ; Wang JB; Lu Y; Zhao YL; Zhou JR; Sun Y; Zhang YC; Ji SQ; Lu DP Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):84-7. PubMed ID: 22730653 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]